NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Duane Larick, Ph.D., interim dean of North Carolina State University's Graduate School and a professor of food, bioprocessing and nutrition sciences, has been named dean of the Graduate School, effective March 1.

As dean, Larick will provide leadership for a graduate program serving more than 7,400 full- and part-time students from across the U.S. and from 85 other countries. NCSU's graduate program administers 220 different graduate degrees (master's, Ph.D. and Ed.D.) across all 10 of NCSU's academic colleges.

Technomark Life Sciences is looking for opportunities to co-develop products with biotechnology and life-science companies.

Technomark, with headquarters in Research Triangle Park, plans to work with partner companies on a risk-sharing basis to advance product development.

"We are very excited to be in a position now to partner with biotechnology and other life science companies on their preclinical or clinical product development," said Allen Hakimi, managing director of Technomark.

Greater Charlotte took time Thursday night to celebrate its successes in biotechnology.

The BioNight celebration highlighted achievements in economic development, research and education.

Dr. Simon Pedder, CEO of Chelsea Therapeutics talked about why he chose to build the now public company in Charlotte - talent, airport hub, quality of life and cost of doing business.

The event also honored:

Joan Siefert Rose, president of the Council for Entrepreneurial Development (CED), announced that the City of Raleigh has issued a proclamation dedicating Monday, Feb. 16 as Biotechnology Day to honor CED's Biotech 2009 conference, Feb. 16 and 17 at the Raleigh Convention Center.

Biotech 2009, CED's 18th annual biotech conference, will unite the Southeast's life science community to celebrate one of the biotech industry's most dynamic regions.

Researchers from North Carolina State University have merged a $147,000 loan from the North Carolina Biotechnology Center with the tools of nanobiotechnology to build NanoVector in Raleigh, one of the state's newest biotech stars.

NanoVector's technology involves the successful modification of a common plant virus so it delivers drugs only to specific cells inside the human body, without affecting surrounding tissue.

Morrisville clinical research software firm Clinipace is among 40 young companies chosen to participate in the Southeast Venture Conference, to be held March 11 and 12 in Atlanta.

The 40 showcase companies from North Carolina, Florida, Georgia, Maryland, South Carolina, Tennessee, Virginia and Washington, D.C. will be presenting to an audience representing more than $60 billion in private equity capital.

Metabolon, a Research Triangle Park company that develops biomarkers for disease detection, has reported finding a molecule in urine that may indicate a man's level of prostate cancer progression.

Metabolon and fellow researchers at the University of Michigan say the discovery could lead to simple, non-invasive tests for men to determine how or whether to treat the disease.

Wilmington-based contract research firm PPD is getting $5 million in milestone payments from Janssen-Cilag, an Alza Corp. affiliate, thanks to successful regulatory approvals in Finland and Sweden for PPD's drug Priligy that treats men with premature ejaculation.

PPD licensed the development rights for Priligy to Alza, calling for PPD to receive a $2.5 million milestone payment for each of the first two national approvals.

Wilmington-based PPD will acquire AbC.R.O., Inc., a contract research organization that operates in Central and Eastern Europe.

As a result, PPD will gain immediate entry into Romania, Bulgaria, Serbia and Croatia, and will strengthen its existing staff and operations in Poland, Russia and Ukraine.

Raleigh-based BioDelivery Sciences has reported encouraging Phase I clinical trial results for Bioral Amphotericin B, the company's lead product candidate incorporating its Bioral drug delivery technology aimed at oral dosing of the antifungal medicine that has been otherwise limited to intravenous use.

The patented Bioral drug delivery technology permits oral dosing by encapsulating drugs in a lipid crystal. The company said the initial test in 48 healthy human volunteers has shown the technology to be safe and well tolerated.

Scientists at the University of North Carolina at Chapel Hill School of Medicine have discovered a gene that, when mutated, or "knocked out," in mice, causes obesity by dampening the body's ability to burn energy while leaving appetite unaffected.

The research could potentially lead to new drugs for treating obesity in humans that do not target the brain, according to study senior author Yi Zhang, Ph.D.

Norris Tolson, president and CEO of the North Carolina Biotechnology Center, will be one of three honored with the prestigious Watauga Medal by North Carolina State University for his distinguished service to the university at the university's Founders' Day Dinner March 9.

Targacept, a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the 11th Annual BIO CEO and Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 10 at 11:00 a.m.

Last year, Exigent Pharmaceuticals of Durham received a $250,000 Small Business Research Loan from the Biotechnology Center. The company is developing compounds that would prevent the spread of drug-resistant bacteria.

This week, TechJournalSouth featured the company in its article "Exigent Pharmaceuticals wants to beat drug-resistant bugs." It is excerpted below.

Raleigh-based BioMarck Pharmaceuticals which was started with the help of a $15,000 loan from the North Carolina Biotechnology Center, said it recently received $990,000 of a $3 million federal grant.

The firm, a 2002 spin-out from North Carolina State University, is conducting successful clinical trials with an inhaled drug to combat the over-secretion of mucus and reduce inflammation. The technology has garnered nearly $16 million in follow-on and venture funding, including the grant from the National Institutes of Health announced this week.